LCTX241220P7500
- 0.00
- 0.000.00%
Lineage Cell Therapeutics Newsroom
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Express News | Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3
Lineage Cell Therapeutics Analyst Ratings
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Announces Target Price $4
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript Summary
Lineage Cell Therapeutics | 10-Q: Q3 2024 Earnings Report
Lineage Cell Therapeutics 3Q Loss/Shr 2c >LCTX
Express News | Lineage Cell Therapeutics Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.779M Beat $1.033M Estimate
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3.8M
Here Are the Major Earnings After the Close Today
Earnings Scheduled For November 14, 2024
Lineage Cell Therapeutics's Earnings Outlook
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Craig-Hallum Initiates Lineage Cell Therapeutics(LCTX.US) With Buy Rating
Earnings Preview: LCTX to Report Financial Results Post-market on November 14
Press Release: Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024